121 related articles for article (PubMed ID: 2189845)
1. Systemic radiotherapy--the new frontier.
Order SE
Int J Radiat Oncol Biol Phys; 1990 May; 18(5):981-92. PubMed ID: 2189845
[TBL] [Abstract][Full Text] [Related]
2. 90Yttrium antiferritin--a new therapeutic radiolabeled antibody.
Order SE; Klein JL; Leichner PK; Frincke J; Lollo C; Carlo DJ
Int J Radiat Oncol Biol Phys; 1986 Feb; 12(2):277-81. PubMed ID: 3005201
[TBL] [Abstract][Full Text] [Related]
3. The theoretical implications and experimental and clinical results of radiolabeled antiferritin.
Order SE
Acta Oncol; 1990; 29(6):689-94. PubMed ID: 2223137
[TBL] [Abstract][Full Text] [Related]
4. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.
Order SE; Stillwagon GB; Klein JL; Leichner PK; Siegelman SS; Fishman EK; Ettinger DS; Haulk T; Kopher K; Finney K
J Clin Oncol; 1985 Dec; 3(12):1573-82. PubMed ID: 2415692
[TBL] [Abstract][Full Text] [Related]
5. Radiolabeled antibodies: results and potential in cancer therapy.
Order SE; Sleeper AM; Stillwagon GB; Klein JL; Leichner PK
Cancer Res; 1990 Feb; 50(3 Suppl):1011s-1013s. PubMed ID: 2404579
[TBL] [Abstract][Full Text] [Related]
6. Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease.
Lenhard RE; Order SE; Spunberg JJ; Asbell SO; Leibel SA
J Clin Oncol; 1985 Oct; 3(10):1296-300. PubMed ID: 4045523
[TBL] [Abstract][Full Text] [Related]
7. Polyclonal 90Yttrium labeled antiferritin for refractory Hodgkin's disease.
Vriesendorp HM; Herpst JM; Leichner PK; Klein JL; Order SE
Int J Radiat Oncol Biol Phys; 1989 Oct; 17(4):815-21. PubMed ID: 2674084
[TBL] [Abstract][Full Text] [Related]
8. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment.
Herpst JM; Klein JL; Leichner PK; Quadri SM; Vriesendorp HM
J Clin Oncol; 1995 Sep; 13(9):2394-400. PubMed ID: 7666099
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy of solid cancers: A review.
Kairemo KJ
Acta Oncol; 1996; 35(3):343-55. PubMed ID: 8679266
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
11. Current status of radioimmunoglobulins in the treatment of human malignancy.
Order SE; Sleeper AM; Stillwagon GB; Klein TL; Leichner PK
Oncology (Williston Park); 1989 May; 3(5):115-20; discussion 122, 129-30. PubMed ID: 2491440
[TBL] [Abstract][Full Text] [Related]
12. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01.
Vriesendorp HM; Herpst JM; Germack MA; Klein JL; Leichner PK; Loudenslager DM; Order SE
J Clin Oncol; 1991 Jun; 9(6):918-28. PubMed ID: 2033428
[TBL] [Abstract][Full Text] [Related]
13. Recurrence of Hodgkin's disease after indium-111 and yttrium-90 labeled antiferritin administration.
Vriesendorp HM; Quadri SM; Andersson BS; Wyllie CT; Dicke KA
Cancer; 1997 Dec; 80(12 Suppl):2721-7. PubMed ID: 9406730
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic applications of radiolabelled antibodies: current situation and prospects.
Larson SM; Carrasquillo JA; Reynolds JC; Hellstrom I; Hellstrom KE; Mulshine JC; Mattis LE
Int J Rad Appl Instrum B; 1986; 13(2):207-13. PubMed ID: 3490462
[No Abstract] [Full Text] [Related]
15. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
[TBL] [Abstract][Full Text] [Related]
17. Antiferritin IgG antibody for isotopic cancer therapy.
Order SE; Klein JL; Leichner PK
Oncology; 1981; 38(3):154-60. PubMed ID: 6259569
[TBL] [Abstract][Full Text] [Related]
18. [Cancer therapy using unsealed radioisotopes-the present and future].
Karasawa K
Gan To Kagaku Ryoho; 2014 Dec; 41(13):2555-8. PubMed ID: 25596049
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric aspects of radiolabeled antibodies for tumor therapy.
Humm JL
J Nucl Med; 1986 Sep; 27(9):1490-7. PubMed ID: 3528417
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
